Does cervical erosion still carry a risk of cancer after receiving the HPV 9-valent vaccine?

Cervical erosion usually refers to cervical ectopic columnar epithelium. Patients with cervical ectopic columnar epithelium who have received the 9-valent HPV vaccine may still develop cancer, although the probability is extremely low. The detailed analysis is as follows:

Cervical ectopic columnar epithelium is a physiological condition. If there is no concurrent infection, it typically presents no clinical symptoms. However, when infection occurs, clinical manifestations such as increased vaginal discharge, external genital itching, postcoital bleeding, and lower abdominal pain may appear. The 9-valent HPV vaccine effectively prevents cervical cancer caused by human papillomavirus (HPV) infection. After vaccination, the body produces specific antibodies, providing strong protection—typically over 90% effectiveness in preventing cervical cancer. Despite its high efficacy, the vaccine does not offer 100% protection; therefore, cancerous changes are still possible even after receiving the 9-valent HPV vaccine.

If patients with cervical ectopic columnar epithelium develop an infection, medications such as doxycycline hydrochloride tablets, azithromycin dispersible tablets, or roxithromycin dispersible tablets may be prescribed under medical supervision. It is important to follow a physician’s advice for regular gynecological examinations and routine cervical cancer screening. Maintaining good personal hygiene habits in daily life also helps prevent HPV infection.